Where are we with Psychedelic Research?
How to Die Well - Part 2: Palliative Treatment with Cannabis
As current paradigms of archaic drug scheduling start to buckle under the weight of mounting empirical evidence, a zeitgeist of how scientific research is phased and how psychedelics might be re-classified is in order. This blogpost (also available as an audio ‘blogcast’) focusses on the current status of MDMA, but it seeks to ask a set of more broadly applicable questions to the road map to mainstream psychedelic legitimacy;
Where are we now? How did We get here? and - perhaps most importantly - where are we going…?
How to Die Well - Part 1
Cannabis has been hailed as a panacea, and as it breaks through the cracks and into mainstream society, we try to sort the bud from the chaff when it comes to its empirical potential to help improve both quality and longevity of life.
The discovery of LSD
We are all shuffling towards death. Could psychedelics help it to be a bit less Parkinsonian and be a bit more Charleston?
MDMA's cultural baggage - cabin or hold?
LSD might have came of age in the counter culture of the 60s and the 70s, but it’s birthing room was an earnest lab in war-torn Europe. The accidental discovery of its profound effects by a brilliant young Swiss chemist on a deranged bike ride serves as a fascinating example of how we humans tend to lurch forward out of our own ignorance through a process of chance observation chased up by planned investigation, occasionally yielding an actual discovery.
MDMA does not carry the same degree of cultural baggage as its’ more hallucinogenic stablemates. As the campaign to promote this compound as a legitimate mainstay of psychiatric treatment gathers momentum, how can we ensure that the cultural conversation threads the needle between irrational over-exuberance and reactionary ignorance?